Sabrina Serani is a senior editor for Targeted Oncology.
Bexmarilimab With SoC Delivers Promising Results in AML
Bexmarilimab shows encouraging results when combined with standard of care treatments for patients with acute myeloid leukemia and myelodysplastic syndromes.
Phase 1/2 Trial of Olaptesed Pegol Shows Potential in Glioblastoma
The CXCL 12 inhibitor delivered a 50% overall survival rate at 18 months in the GLORIA trial, and its manufacturer intends to seek FDA guidance on further trial design.
FDA Approves Companion Diagnostic for Selpercatinib in RET Fusion+ Solid Tumors
The next-generation diagnostic tool is approved for companion diagnostic use with selpercatinib for select solid locally advanced and metastatic tumors.
T-IELs Could Hold the Key for CRC Immunotherapy
Researchers identified different functions of groups of intraepithelial T cells (T-IELs) throughout the gastrointestinal tract, which could help inform future immunological treatment for patients with colorectal cancer.
HT Scoring Identifies Risk and Outcomes of CAR T Therapy for MCL
The CAR-HEMATOTOX score was positively associated with identifying the risk of poor treatment outcomes for patients with mantle cell lymphoma treated with chimeric antigen receptor T-cell therapy.
FDA Accepts BLA Resubmission of OBI Presentation of Pegfilgrastim-cbqv
The FDA completed its inspection of a third-party filler, and no additional data or trials have been requested for resubmission.
Investigational Assay Shows Promise as Prognostic Tool for Prostate Cancer
Investigators presented results from new studies at the 2023 ASTRO Meeting. The data showcase a new assay’s performance in predicting metastasis-free survival and distant metastasis.
Phase 3 Trial for Venetoclax for Multiple Myeloma Misses Its Primary End Point
The improvement in progression-free survival in the venetoclax arm of the study was not statistically significant compared to the control arm but results still trend positively.
Pembrolizumab Improves DFS in Muscle-Invasive Urothelial Carcinoma
Meeting a primary end point, KEYNOTE-123 study shows promise for pembrolizumab as an adjuvant muscle-invasive bladder cancer treatment.
FDA’S ODAC Votes Yes to Eflornithine for Pediatric Neuroblastomas
The decision marks the first time the FDA has relied on a single externally controlled trial to support a potential approval in oncology.
SAR-Bombesin Treatment in Prostate Cancer Begins
The phase 1/2 trial is evaluating 64Cu/67Cu SAR-Bombesin for diagnosis and treatment of castrate resistant prostate cancer.
FDA Grants Orphan Drug Designation to BDC-1001 in Gastric Cancer
Phase 2 studies are investigating BDC-1001 in HER2-positive gastroesophageal, colorectal, breast, and endometrial cancers.
Motixafortide Shows Benefit to First-Line Pancreatic Cancer Treatment in Phase 2 Trial
An MCGN drug combination shows potential to be more effective than standard chemotherapy alone for treatment-naïve metastatic pancreatic cancer.
Mirvetuximab Soravtansine Prolongs Survival in Ovarian Cancer Subset
Results of the phase 3 MIRASOL study evaluating mirvetuximab soravtansine for platinum-resistant ovarian cancer will be announced at an upcoming meeting.
GC012F CAR T Shows 100% Complete Response Rate in Multiple Myeloma
Researchers presented updated results from longer-term follow-up studies of GC012F for newly-diagnosed multiple myeloma treatment at the International Myeloma Society Annual Meeting.
2 Clarke Drive Cranbury, NJ 08512